EUVIMEDEUVIMED entdecken
Open Access

FcRn inhibitors for myasthenia gravis

Laura M White, Fiona J Clay, Anne-Marie Forbes, Ryan Yann Shern Keh, James B Lilleker, Jennifer Spillane, Karen Storms, Katherine C Dodd iD, Jon Sussman

Cochrane Database of Systematic Reviews · 2025

DOI: 10.1002/14651858.cd016097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cochrane Database of Systematic Reviews, 2025. Verfasst von Laura M White und 8 weiteren Autor:innen. Beteiligte Einrichtung: Lancaster Medical School, Lancaster University, Lancaster, UK. Hauptthemen laut MEDLINE: Myasthenia Gravis, Receptors, Fc, Histocompatibility Antigens Class I. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of FcRn inhibitors for the maintenance treatment of myasthenia gravis in adult participants compared with control treatment (placebo, standard-of-care therapy, an alternative FcRn inhibitor, or an alternative immunomodulatory therapy). We will evaluate the efficacy of the treatment by the effect on disease severity and functional impairment, as assessed using a measurement tool validated for use in myasthenia gravis. Where possible, we will assess whether the effects of FcRn inhibitors differ according to different participant subgroups or different treatment regimens, or both. These data will be used to inform policymakers on the participant subgroups most likely to benefit from treatment and the most efficacious treatment regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisReceptors, FcHistocompatibility Antigens Class IHumansRandomized Controlled Trials as TopicAdult

Substanzen

Receptors, FcFc receptor, neonatalHistocompatibility Antigens Class I

Autor:innen und Institutionen

  • Lancaster Medical School, Lancaster University, Lancaster, UK.
  • Department of Neurology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
  • Department of Forensic Medicine, Monash University, Southbank, Australia.
  • University of Tasmania, Hobart, Australia.
  • Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford, UK.
  • The University of Manchester, Manchester, UK.

ORCID-Profile: Katherine C Dodd

Zitieren

APA

White, L. M., Clay, F. J., Forbes, A. M., Keh, R. Y. S., Lilleker, J. B., Spillane, J., Storms, K., Dodd, K. C., & Sussman, J. (2025). FcRn inhibitors for myasthenia gravis. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd016097

Vancouver

White LM, Clay FJ, Forbes AM, Keh RYS, Lilleker JB, Spillane J, et al. FcRn inhibitors for myasthenia gravis. Cochrane Database of Systematic Reviews. 2025. doi:10.1002/14651858.cd016097

BibTeX
@article{White2025,
  author = {White, Laura M and Clay, Fiona J and Forbes, Anne-Marie and Keh, Ryan Yann Shern and Lilleker, James B and Spillane, Jennifer and Storms, Karen and Dodd, Katherine C and Sussman, Jon},
  title = {FcRn inhibitors for myasthenia gravis},
  journal = {Cochrane Database of Systematic Reviews},
  year = {2025},
  doi = {10.1002/14651858.cd016097}
}
Kostenlos starten →